

A Thiazide Test for the Diagnosis of Renal Tubular Hypokalemic Disorders

Giacomo Colussi,^{*†} Alberto Bettinelli,[‡] Silvana Tedeschi,[§] Maria Elisabetta De Ferrari,[†] Marie Louise Syrén,^{||} Nicolò Borsa,[§] Camilla Mattiello,[§] Giorgio Casari,[¶] and Mario Giovanni Bianchetti^{**}

^{*}Unité Operative Nefrologia, Ospedale di Circolo e Fondazione Macchi, Varese, Italy; [†]Unité Operative Nefrologia, Dialisi e Trapianto Renale, Ospedale Niguarda-Ca' Granda, Milano, [‡]Unité Operative Pediatria, Ospedale Mandic, Merate (Lecco), [§]Laboratorio di Genetica Medica, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano, ^{||}Istituto di Pediatria e Neonatologia, Università degli Studi di Milano, Milano, and [¶]Unità di Genetica Molecolare Umana, DIBIT, Istituto Scientifico San Raffaele, Milano, Italy; and ^{**}Servizio di Integrazione di Pediatria, Mendrisio e Bellinzona, Switzerland

Although the diagnosis of Gitelman syndrome (GS) and Bartter syndrome (BS) is now feasible by genetic analysis, implementation of genetic testing for these disorders is still hampered by several difficulties, including large gene dimensions, lack of hot-spot mutations, heavy workup time, and costs. This study evaluated in a cohort of patients with genetically proven GS or BS diagnostic sensibility and specificity of a diuretic test with oral hydrochlorothiazide (HCT test). Forty-one patients with GS (22 adults, aged 25 to 57; 19 children-adolescents, aged 7 to 17) and seven patients with BS (five type I, two type III) were studied; three patients with "pseudo-BS" from surreptitious diuretic intake (two patients) or vomiting (one patient) were also included. HCT test consisted of the administration of 50 mg of HCT orally (1 mg/kg in children-adolescents) and measurement of the maximal diuretic-induced increase over basal in the subsequent 3 h of chloride fractional clearance. All but three patients with GS but no patients with BS and pseudo-BS showed blunted (<2.3%) response to HCT; patients with BS and the two patients with pseudo-BS from diuretic intake had increased response to HCT. No overlap existed between patients with GS and both patients with BS and pseudo-BS. The response to HCT test is blunted in patients with GS but not in patients with BS or nongenetic hypokalemia. In patients with the highly selected phenotype of normotensive hypokalemic alkalosis, abnormal HCT test allows prediction with a very high sensitivity and specificity of the Gitelman genotype and may avoid genotyping.

Clin J Am Soc Nephrol 2: 454-460, 2007. doi: 10.2215/CJN.02950906

Mutations of several genes that are involved in Na/fluid reabsorption along the distal nephron are the cause of tubular disorders that are characterized by chronic hypokalemic alkalosis and normotensive, hyperreninemic hyperaldosteronism, including Gitelman syndrome (GS; OMIM 263800) and Bartter syndrome (BS) types I to V (1-3) (OMIM 241200, 601678, 607364, 602522, and 601199). Chronic normotensive hypokalemia and alkalosis may also be acquired as a result of known or unknown diuretic use, anorexia/bulimia, and laxative abuse (4-6). Clinical history and biochemical workup may not allow definite diagnosis, especially concerning the different types of tubular disorders. Genetic diagnosis is now feasible for all known genes that are responsible for GS and BS, but in everyday practice, it remains not easily available for the clinician and, for the geneticist, costly, cumbersome, and time-consuming as a result of the great di-

mension of most genes, lack of hot-spot mutations, and the very large number of mutations described. Furthermore, in approximately 40% of patients with GS, only a single heterozygous mutation in the SLC12A3 gene is detected (7), so further examination of a second gene is usually necessary.

Tests with diuretics have been used in the past to diagnose tubular disorders (8-12) and nontubular conditions (5); however, genetic confirmation of the supposed diagnosis was rarely, if ever, available. We present the diagnostic yield of a test with the thiazide diuretic hydrochlorothiazide (HCT) in a large cohort of patients with genetically proven GS and BS types I and III and in three additional patients with nontubular chronic hypokalemia. The results indicate that the thiazide test may correctly characterize most patients with GS and thereby reduce the need for genetic testing in a substantial fraction of patients.

Materials and Methods

Patients

A total of 51 patients were studied; all had chronic normotensive and hyperreninemic hypokalemia of uncertain origin, and their final diagnosis was GS in 41 patients, BS in seven (type I in five, type III in two), surreptitious diuretic use in two, and alimentary disturbance (vomiting) in one. They were studied and followed up at two adults' hospitals in Milan and Varese and two children's hospitals in Milan and Merate, all in Italy.

Received September 4, 2006. Accepted January 20, 2007.

Published online ahead of print. Publication date available at www.cjasn.org.

Address correspondence to: Dr. Giacomo Colussi, U.O. Nefrologia, A.O. Ospedale di Circolo e Fondazione Macchi, Viale Borri, 57, 21100 Varese, Italy. Phone: +39-332-278208; Fax: +39-332-393018; E-mail: giacomo.colussi@ospedale.varese.it

The diagnosis of GS and different type of BS was supported by genetic testing, disclosing significant mutations of pertinent genes in homozygous or compound heterozygous state (Tables 1 through 3). Seventeen patients (15 with GS and two with BS) with a single heterozygous, nonpolymorphic mutation and consistent phenotype were also included, because it is not uncommon, at least in GS, that the second mutation is missed (7). Exclusion of heterozygous cases would not change the results and interpretation of data.

Molecular Diagnostics

Genetic testing was carried out on genomic DNA from peripheral blood cells according to published methods for the SLC12A3 (13,14), SLC12A1 (15), CLCNKB (16,17), and KCNJ1 (18) genes. Some patients (the earliest cases) underwent a mutational screening by means of single-strand conformational polymorphisms analysis, and when an abnormal migration pattern was observed, a sequence was performed on the coding region and its intron-exon boundaries. More recent patients were defined only by direct sequencing. The gene that was most likely to account for the phenotype in individual patients was analyzed first (SLC12A3 for Gitelman phenotype, SLC12A1 and/or KCNJ1 for "antenatal" Bartter phenotype, and CLCNKB for "classical" Bartter phenotype without nephrocalcinosis); however, in the case of negative results or of heterozygous mutations for the candidate gene and in the presence of strong clinical suspicion, other pertinent genes also were evaluated (CLCNKB in both Gitelman and Bartter phenotype and the untested gene in Bartter phenotype). No genetic study was performed in the three patients with nontubular disorders.

Study Design and Thiazide Test

All of the patients were studied either as outpatients (mostly adults) or as inpatients (mostly children-adolescents); at least a daily urine

Table 1. Clinical and genetic data in 19 pediatric patients with SLC12A3 mutations (Gitelman syndrome)^a

Patients	Gender	Age (yr)	Mutation ^b	Type
8	M	13	D62N homo	M/M
20	M	15	Del. ex.26 homo ^c	F/F
39	F	16	C421G ^c /C985Y	M/M
B1	M	11	A464T/–	M/–
B2	F	12	G186D/M581K ^c	M/M
B3	F	11	G650R/R852C	M/M
B10	M	7	G731R/IVS22–2A>G ^c	M/SS
B11	M	7	V677M/R209W	M/M
B12	M	7	A401fs homo	F/F
B13	F	16	R209W/G186D	M/M
B14	M	15	R958G homo	M/M
B15	M	15	T383M ^c /R80fs ^c	M/F
B16	M	17	R852C/–	M/–
B18	M	10	R80fs ^c /–	F/–
B19	F	8	S615L/R642H	M/M
B20	F	10	T163M/–	M/–
B21	F	8	T163M/–	M/–
B22	M	17	D839N/IVS3 –1G>A ^c	M/SS
B23	F	7	R862P ^c /Q95fs	M/F

^aSLC12A3 sequence numbering according to GenBank entry X91220. del#, exon deletion; fs, frameshift; homo, homozygous mutation; IVS(#), intron; M, missense mutation; F, frameshift mutation; N, nonsense mutation (stop); SS, splice-site mutation; –, undetected mutation.

^bGenetic variants are shown for the two alleles.

^cUndescribed mutations.

Table 2. Clinical and genetic data in 22 adult patients with SLC12A3 mutations (Gitelman syndrome)

Patients	Gender	Age (yr)	Mutation ^a	Type
4	F	53	W699R ^b /R852C	M/M
5	M	57	C985Y homo	M/M
6	F	26	G439S/–	M/–
9	M	27	F765fs/–	F/–
11	F	36	R209W/–	M/–
13	M	27	T820fs ^b homo	F/F
14	F	43	S615L/–	M/–
16	F	32	G439S/–	M/–
17	F	37	G439S/–	M/–
19	M	26	Del. ex.26 homo ^b	F/F
21	M	40	R852C/–	M/–
22	F	36	I895F ^b /–	M/–
23	M	27	C985Y/–	M/–
24	F	35	R642G homo	M/M
25	M	25	C985Y/A401fs	M/F
26	M	52	K497X/T7fs ^b	N/F
28	M	43	R958G/IVS24 + 1G>T	M/SS
29	F	31	S615L homo	M/M
30	M	39	G316A/A464T	M/M
33	F	31	C421X ^b /S615L	N/M
35	F	33	W425X ^b /–	N/–
36	F	26	A401fs/T392I ^b	F/M

^aGenetic variants are shown for the two alleles.

^bUndescribed mutations.

collection was performed on an unrestricted diet for electrolyte excretion, and fasting plasma levels were taken in the morning. A washout period of at least 7 d was allowed between withdrawal of any therapy and both general biochemical evaluation and thiazide test; however, oral KCl and Mg salts (any dosages), when already in use, were maintained or stopped the day before the test.

The thiazide test (HCT test) was performed as described previously (10); in brief, after an overnight fast, the patients were kept recumbent for 4 h and were invited to drink tap water (10 ml/kg body wt) to facilitate spontaneous voiding. After two 30-min "basal" clearances, 50 mg of HCT (in adults and older adolescents) or 1 mg/kg body wt (in children) was administered orally, and six additional 30-min clearances were performed. Blood samples (for measurement of Na, Cl, K, and creatinine as GFR marker) were taken at times 60 and 240 min, and urine was collected every 30 min by spontaneous voiding and analyzed for Na, Cl, K, and creatinine. A simplified quantification of the diuretic effect was performed by choosing maximal increases of urine electrolyte excretion over mean basal levels (*i.e.*, maximal excretion at any time minus the mean of the two basal clearances) as the test result. For accounting for possible incompleteness of urine collections, electrolyte excretion was evaluated as fractional excretion (FE; with creatinine as a GFR marker) rather than quantitative terms (10).

Reference values for biochemical parameters were from our laboratory's data on the healthy general population on unrestricted diet; control results for the HCT test were from 12 healthy people aged 13 to 61 yr. All adult patients and one parent of patients who were younger than 18 yr gave their informed consent to all of the procedures considered for the diagnostic workup.

Statistical Analyses

Unpaired *t* test was used to disclose significant differences (with $P \leq 0.05$) in biochemical data between the groups; relationships between parameters were evaluated by correlation analysis using a computer program.

Table 3. Clinical and genetic data in seven patients with Bartter syndrome (types I and III, genes SLC12A1 and CLCNKB, respectively)^a

Patients	Gender	Age (yr)	Gene and Mutation ^b	Type
15	M	28	CLCNKB (Del. ex.6 homo)	F/F
B4	F	4	SLC12A1 (R302fs/D12fs ^c)	F/F
B5	F	8	SLC12A1 (C461R/-)	M/-
B7	F	11	SLC12A1 (L522fs ^c /-)	F/-
B8	F	20	SLC12A1 (R302fs homo)	F/F
B9	M	14	SLC12A1 (R116H ^c /G652S ^c)	M/M
B17	M	24	CLCNKB (P124L homo)	M/M

^aSequence numbering: CLCNKB according to GenBank entry Z30644; SLC12A1 according to GenBank entry U58130.

^bGenetic variants are shown for the two alleles.

^cUndescribed mutations.

Results

Individual clinical and genetic patient data are shown in Tables 1 through 3, general biochemical group profile is shown in Table 4, and group thiazide test results are shown in Table 5 (where the prefix "B" denotes patients from the children's hospitals). Data from several patients have already been described (13,14,19,20); there were three brother/sister couples (patients 16 and 17, 19 and 20, and B20 and B21). Patients with GS are divided into two separate groups according to age (*i.e.*, 22 adults, >18 yr; and 19 children-adolescents, <18 yr). This is because most of the latter were seen in the children's hospitals and performed the HCT test with <50 mg of the diuretic; moreover, the two groups did not differ as for biochemical data, pattern of mutations, symptoms, and response to HCT test (Tables 4 and 5, and Figure 1). Patients with mutations in Henle's loop genes (SLC12A1 and CLCNKB) were analyzed together (BS group); because of the small number, no age differences were considered. The three patients with nontubular hypokalemia (PB) were three women with surreptitious diuretic use (two patients: furosemide by biochemical screen and self-admission) and postalimentary vomiting (one patient, self-admission). The diuretic HCT test in these patients had

been planned because of previous diagnosis of tubular disorder elsewhere or diagnostic uncertainties.

In our cohort of patients, the majority of mutations in SLC12A1, SLC12A3, and CLCNKB genes were point mutations (missense, nonsense splice site, and small deletions/insertions). No hot spot could be identified. All of the variants found were considered to be loss-of-function mutations: 28 (on a total of 76 mutated alleles found) were splice-site mutations, nonsense, and frameshift, leading to a stop codon, and the remaining missense mutations in 48 mutated alleles were either previously published as inactivating mutations or are novel variants targeting on amino acids that are conserved among the species. None of the novel mutations were found in 100 control chromosomes.

Major biochemical differences between groups were lower creatinine clearance in PB, lower plasma magnesium levels in GS (both adults and children-adolescents), higher sodium and chloride daily urine excretion (representing more abundant dietary intake in an adult population) in adult GS, reduced urine Ca excretion (as daily U_{Ca}/U_{Cr} ratio) in GS (both adults and children-adolescents), and increased Ca excretion in BS. In individual patients, plasma Mg was normal (>1.6 mg/dl) in 15

Table 4. Blood and urine biochemical data in patient groups^a

Group (n)	C_{Cr} (ml/min per 1.73)	P_K (mmol/L)	P_{Cl} (mmol/L)	P_{HCO_3} (mmol/L)	P_{Mg} (mg/dl)	P_{renin} (Ratio) ^b	P_{aldo} (Ratio) ^b	U_{NaV} (mmol/d)	U_{ClV} (mmol/d)	U_{MgV} (mg/d)	U_{Ca}/U_{Cr} (mg/mg)
GS _{ad} (22)	100 ± 22	2.6 ± 0.3	97 ± 3	30.9 ± 3.8	1.4 ± 0.3 ^c	3.2 ± 2.7	1.4 ± 1.4	227 ± 109 ^d	240 ± 144 ^e	89 ± 35	0.06 ± 0.05
GS _{a-c} (19)	132 ± 29	2.7 ± 0.3	96 ± 2	29.4 ± 2.6	1.6 ± 0.3 ^c	3.8 ± 2.1	1.3 ± 1.0	153 ± 66	150 ± 78	90 ± 47	0.04 ± 0.02
BS (7)	106 ± 33	2.5 ± 0.2	100 ± 4	29.7 ± 4.3	2.0 ± 0.4	3.1 ± 1.9	1.8 ± 0.6	98 ± 81	142 ± 81	66 ± 25	0.46 ± 0.36 ^d
PB (3)	60 ± 31 ^f	2.6 ± 0.3	91 ± 4 ^f	32.7 ± 5.4	2.1 ± 0.4	5.4 ± 4.4	15.3 ± 19.4	117 ± 112	183 ± 227	31 ± 6 ^g	0.13 ± 0.04 ^g
n/range	>80	3.5 to 4.5	95 to 110	22 to 28	1.6 to 2.2	<1	<1	Dietary intake ^h	Dietary intake ^h	25 to 180	0.03 to 0.20

^aData are means ± SD. aldo, aldosterone; BS, Bartter syndrome; C_{Cr} , creatinine clearance; GS_{a-c}, Gitelman syndrome in children-adolescents; GS_{ad}, Gitelman syndrome in adults; P_X , plasma levels of X; PB, nontubular hypokalemia; U_X/V_X , urine excretion of X; U_{Ca}/U_{Cr} , ratio between calcium and creatinine excretion.

^bThe ratio between individual values and maximal normal level for the assay.

^c $P < 0.01$ versus BS and PB.

^d $P < 0.01$ versus all other groups.

^e $P < 0.02$ versus GS_{a-c} and BS.

^f $P < 0.05$ versus all other groups.

^g $P < 0.02$ versus GS_{ad} and GS_{a-c}.

^hIn our adult population: 60 to 380 mmol/d.

Table 5. Group results of HCT test^a

Group (n)	FE _{Nab} (%)	FE _{NaMax} (%)	ΔFE _{Na} (%)	FE _{Clb} (%)	FE _{ClMax} (%)	ΔFE _{Cl} (%)	FE _{Kb} (%)	FE _{KMax} (%)	ΔFE _K (%)
GS _{ad} (22)	1.03 ± 0.53 ^b	1.93 ± 0.77 ^{c,d}	0.90 ± 0.58 ^{c,d}	1.32 ± 0.67 ^e	2.60 ± 1.12 ^{c,d}	1.28 ± 0.78 ^{c,d}	25.1 ± 15.9	30.0 ± 14.1	5.0 ± 8.0
B17 (18)	0.83 ± 0.41 ^e	1.17 ± 0.72 ^{c,d}	0.34 ± 0.43 ^{c,d}	2.71 ± 1.40	3.90 ± 1.69 ^{d,f}	1.19 ± 0.78 ^{c,d}	33.3 ± 16.4 ^c	36.9 ± 15.2 ^e	3.3 ± 10.1 ^e
BS (7)	0.44 ± 0.30 ^f	4.66 ± 2.36	4.13 ± 2.32 ^e	1.39 ± 1.53	9.74 ± 5.80 ^e	8.35 ± 4.92 ^f	23.9 ± 14.9	51.4 ± 42.5 ^e	27.5 ± 39.2
PB (3)	0.38 ± 0.50 ^f	3.36 ± 0.73	2.98 ± 1.07	0.70 ± 0.78 ^c	6.43 ± 1.70	5.73 ± 2.42 ^e	8.6 ± 5.8	66.6 ± 51.1 ^f	58.0 ± 47.9 ^f
Control (12)	1.49 ± 0.75	4.13 ± 1.10	2.64 ± 0.88	2.15 ± 1.26	5.73 ± 1.58	3.58 ± 1.00	16.99 ± 7.03	26.0 ± 8.0	10.0 ± 6.6

^aData are means ± SD. b, basal clearances; Δ, maximal increase; EE_X, fractional excretion of X; HCT, hydrochlorothiazide; Max, maximal clearances.

^bP < 0.05 versus BS.

^cP < 0.001 versus controls.

^dP < 0.001 versus BS.

^eP < 0.05 versus controls.

^fP < 0.01 versus controls.




Figure 1. Individual hydrochlorothiazide test results (as maximal increase in fractional chloride clearance) in patient groups. Values are expressed in a log scale; horizontal line corresponds to the lower normal value (2.3%). GS, Gitelman syndrome (▲; GS_{2d}; △; GS_{a-c}); BS, Bartter syndrome (●, BS type I; ○, BS type III); PB, pseudo-Bartter syndrome (◆, furosemide abuse; ◇, habitual vomiting).

patients with GS (six adults and nine children-adolescents), in all but two patients with BS (one BS type I and one BS type III), and all three patients with PB; urine Ca excretion (as daily U_{Ca}/U_{Cr} ratio) was >0.07 mg/mg (a conventional definition of “normocalciuria”) (21) in 10 patients with GS (seven adults and three children-adolescents), all three patients with PB, and all but one patient with BS (type III, with a low 0.04 U_{Ca}/U_{Cr} ratio). In remaining six patients with BS, U_{Ca}/U_{Cr} was higher than the higher normal limit of 0.20.

Group results of HCT tests are shown in Table 5, and individual data of maximal Fe_{Cl} changes (ΔFE_{Cl}) are shown in Figure 1. Patients with GS but not BS and PB had blunted diuretic effect as indicated by much lower sodium and chloride postdiuretic urine excretion and maximal increase, as already reported (8–10). The chloruretic effect was higher than the natriuretic effect, this difference having traditionally been explained, in clearance studies, by greater Na than Cl reabsorption in tubular segments past the site of the diuretic action (22). For this reason, Cl data are usually preferred to Na in diuretic-based clearances (5,8–10,23); however, as regards this study, there were minor qualitative differences in data results and

interpretation considering Na rather than Cl clearance results. Considering a maximal diuretic-induced increase (Δ) of FE_{Cl} of 2.3% (the lower observed value in control subjects) as the lower normal response, all but three patients with GS (two adults and a 10-yr-old boy) had lower than normal ΔFE_{Cl} values; all patients with BS and the three patients with PB had higher ΔFE_{Cl} than 2.3% (range 3.10 to 17.68%), with mean levels statistically higher than in control subjects (Table 5, Figure 1). In four patients with BS and the two patients with PB from diuretic abuse, ΔFE_{Cl} was above the maximal level in control subjects of 5.36%. The remaining three patients with BS and normal ΔFE_{Cl} were the two patients with BS type III and a patient with BS type I with only a heterozygous mutation (Figure 1). This latter 11-yr-old girl did not have mutations in the KCNJ1 gene and had a typical phenotype of “antenatal” BS with polyhydramnios, preterm birth, and early-onset nephrocalcinosis; therefore, the diagnosis of BS type I was maintained despite that a second SLC12A1 mutation was not found. The three patients with GS and normal HCT test results were either compound (one patient) or single (two patients) heterozygotes.

Most notable, there was almost no overlap between GS and BS: Only one patient with GS had a very high, seemingly unexplainable, ΔFE_{Cl} of 3.6%; we could not repeat the test in this patient to exclude possible laboratory errors. The other two patients with “normal” HCT test had a ΔFE_{Cl} at the lower normal limits, respectively 2.55 and 2.60%.

Diagnostic sensitivity of ΔFE_{Cl} (<2.3%) was 38 (93%) of 41, and specificity was 100%. Of note, close results were observed in the three brother/sister couples: ΔFE_{Cl} was 0.65% in both patients 16 and 17, 1.1 and 0.8% in patients 19 and 20, and 0.53% and 1.27% in patients B20 and B21, respectively. There were no significant correlations between ΔFE_{Cl} (independent variable) and plasma K and Mg levels or urinary Ca excretion (dependent variables) in any group of patients or control subjects. There were no adverse symptoms to diuretic test in any patient or control subject; compliance with urine collection was excellent, so the test could be correctly performed, always with spontaneous voiding, also in children as young as 7 yr old and, with a parent’s aid, in a 4-yr-old girl.

Discussion

Genetic testing has become a powerful means to diagnose individual entities of the group of monogenetic tubular disorders that present as chronic normotensive, hyperreninemic hypokalemia and alkalosis. Most of the genes responsible, when inactivated by mutations of specific abnormalities of tubular solute reabsorption that underlie each of these conditions, have been defined, allowing definite molecular diagnosis (13,15,17,18,23–26). Despite these premises, genetic diagnosis of hypokalemic disorders still remains largely confined to a few laboratories that specialize in rare diseases far away from the clinic. Furthermore, genotyping turns out to be complex and time-consuming for several reasons: Most genes of interest have huge dimensions (spanning from five exonic regions for ROMK to 26 exons for SLC12A1 and SLC12A3); the number of recognized mutations in each gene is very large and evenly distributed along the whole gene without any hot spot, requiring long and costly sequencing procedures in every sample for their demonstration; or several mutations (mostly in SLC12A3 gene) are still missed, likely as a result of their localization in the unknown regulatory regions or of complex mechanisms such as silent polymorphisms that lead to exon skipping (27). In addition, there exists a clinical overlap between individual disorders, so negative workup for a gene does not exclude mutations in other genes. As an example, phenotypic overlapping is widely known between patients with mutations in CLCNKB and SLC12A3 genes and between mutations in all BS-causative genes (2,16,28,29). Intrafamilial heterogeneity in phenotypic expression of a same mutation is also well described (29,30). Therefore, precise phenotypic characterization of individual tubular disorders may greatly help restrict the genetic workup; however, traditional parameters, such as age, plasma Mg, and urine Ca excretion, lack specificity. Fifteen of our 41 patients with GS had normal plasma Mg, and 10 had “normal” (although arbitrarily defined) Ca excretion. Of our seven patients with BS, one patient with BS type III had low Ca excretion and two had hypomagnesemia. Another confounding factor is that the same electrolyte and hormonal profile may result from a genetic disease or an acquired, still unapparent, cause, such as diuretic intake, bulimia, or gastrointestinal losses; although a suggestive urinary electrolyte profile may be a clue (4–6), general phenotypic profile may be difficult to differentiate from tubulopathy.

We have seen that blunted natriuretic and chloruretic response to HCT correctly recognizes GS from BS and from PB from concealed loop diuretic use and vomiting. The test is very simple to perform and interpret, has very high sensitivity and specificity, and may substantially improve the phenotyping of

tubular hypokalemic disorders. As an example, Table 6 shows two representative patients with “ambiguous” phenotype in which diuretic test suggested the correct final diagnosis.

Diuretic challenge was historically used to characterize the tubular site and underlying cause(s) of hypokalemic tubular disorders (8–12), and differential response patterns in different patients had allowed anticipation of a different molecular background for these disorders and their genetic heterogeneity. Individual hypokalemic tubular disorders are in fact a natural model of chronic administration of diuretics of different classes (2). Because diuretics of individual classes exert their effect by selectively interacting with specific tubular transporters/channels (31), it is a logical expectation that abnormal functional activity of their target proteins results in parallel changes in pharmacologic response. Our results confirm that diuretics may allow selective evaluation of individual tubular transporters in clinical practice and that this information may translate into reliable diagnostic results. All but three patients with proved mutations in the SLC12A3 gene were expected to have impaired function/activity of the thiazide-inhibitable Na-Cl co-transporter, but none with mutations of transporter/channels not inhibited by thiazides or without genetic disorders showed blunted HCT response. There was a wide variability in diuretic response in GS, from completely abolished to near normal, suggesting corresponding variability in functional equivalence of underlying mutations. Close responses to the diuretic were observed in at least two of the three pairs of brother/sisters, an indirect confirmation that the test result is a measure of the degree of functional impairment of the transporter. There was some overlap in diuretic effect between healthy individuals and GS, suggesting that the HCT test, in this simplified protocol, may not be a precise measure of the thiazide carrier activity “*in vivo*.” Alternatively, the activity of the thiazide carrier may undergo modulation by physiologic factors (*e.g.*, volume status, dietary Na intake, filtrate delivery to the distal convoluted tubule) that were not taken into account by our protocol. Most important, there was a fair differentiation, by HCT test, between types of tubular disorder (patients with a distal convoluted tubule defect [GS] and those with Henle’s loop defect [BS in a broad sense]). Therefore, if confirmed in a larger number of patients (specifically BS patients), the HCT test might easily allow differentiation of GS from BS of any type, especially BS type III, the condition most likely to overlap with the GS phenotype.

We did not find in our patients with GS any apparent correlation between quantitative response to HCT and type of mu-

Table 6. Clinical phenotype, genotype, and HCT test result in two representative patients

Patient	Gender	Age (yr)	P _K (mM)	P _{Mg} (mg/dl)	U _{Ca} /U _{Cr} (mg/mg)	Symptoms	ΔFE _{Cl} (%)	Diagnosis		Gene Mutation
								Clinical ^a	HCT ^b	
33	F	23	2.30	1.80	0.12	Tetany, nocturia	0.65	BS (type III)	GS	SLC12A3
B17	M	24	2.29	0.96	0.04	Tetany, polyuria	3.45	GS	BS, possibly type III	CLCNKB

^aAccording to the biochemical profile.

^bAccording to the HCT test.

tations (missense rather than nonsense or frameshift) or with plasma K and Mg levels, urine Ca excretion, or severity of clinical symptoms. Several explanations may be envisaged for these observations: It is difficult to predict the effects of any type of mutations (missense, nonsense, frameshift, or splice site) on the protein fate (protein synthesis, intrinsic activity, routing, or membrane expression) (32,33). In addition, *in vivo* compensatory adaptations in other transport mechanisms may occur along the nephron in response to chronic inactivation/inhibition of a single transport system, as well described for long-term administration of diuretics (31).

In this context, of great interest is the enhanced response to HCT in most patients with a Henle's loop defect and the two patients with abuse of the Henle's loop diuretic furosemide. Enhanced HCT effect suggests a compensatory hyper-reabsorption of tubular fluid in sites past the loop of Henle, specifically the distal convoluted tubule, where thiazides exert their diuretic action. This is well known to occur in long-term use of loop diuretics and is the basis for concurrent thiazide and loop diuretic use in severe edematous disorders (34,35). Irrespective of its explanation, enhanced HCT effect in patients with hypokalemia and alkalosis is a clue to the diagnosis of a Henle's loop defect or concealed intake of a loop diuretic.

Our two patients with BS type III seemed to have a lower HCT response (within the high-normal range) than patients with BS type I. This might be in keeping with the suggestion by others (36) that CLCNKB mutations might secondarily impair NaCl reabsorption also at the thiazide carrier level; this is because the CLC-Kb channel might be the main basolateral chloride exit route in distal convoluted tubule as well as Henle's loop cells, as demonstrated for the homologous CLC-K2 channel in mouse (37). Inactivating mutations of CLCNKB in BS type III might impair chloride exit from the cells and NaCl reabsorption from the tubule lumen both in Henle's loop and in thiazide-sensitive sites. Our data showing lower than expected NaCl reabsorption in thiazide-sensitive sites in BS type III might be an indirect confirmation that mouse data hold true also for humans; in addition, they suggest that normal HCT response might differentiate BS type III from both other types of BS (with higher test responses) and GS (with blunted response). A larger number of patients with BS type III are certainly needed to confirm the specificity of HCT effects in BS type III in relation to both other types of BS and GS.

Extensive use of the thiazide test in the diagnosis of renal tubular hypokalemic disorders may have practical limitations: It may not be feasible in very young children, who are unable to comply with urine collections; also, in patients who are already under treatment with high-dosage antiprostaglandin or antialdosterone drugs and for whom treatment withdrawal might be poorly acceptable, the test cannot be recommended because we have not tested how and how much HCT effect may be affected by other drugs that act on tubular reabsorptive processes. In these instances, direct genetic testing seems preferable. Also in patients with surreptitious thiazide intake, one might anticipate unpredictable results to our HCT test. Although we did not observe adverse symptoms in our patients, patients with Henle's loop defect (whose fluid homeostasis

largely depends on the distal convoluted tubule function) should be carefully watched for signs of acute volume depletion.

Conclusion

We have shown that the response to a standard dosage of HCT is blunted in patients with GS but not in patients with mutations of Henle's loop transporters/channels or with non-genetic hypokalemia. In patients with the highly selected phenotype of normotensive hypokalemic alkalosis, reduced HCT test results allow prediction with a very high sensitivity and specificity of the GS genotype, so we plan in prospect to avoid genotyping patients with reduced HCT test and a phenotype consistent with GS. In occasional patients with GS phenotype and normal or high HCT test result, we would examine as a first option the CLCNKB gene; in patients with equivocal phenotype and very high response to HCT test, we would perform a diuretic screen (at least in adults) before undergoing genotyping.

Acknowledgments

We thank the "Associazione per il Bambino Nefropatico" for financial support for molecular genetics evaluations.

Disclosures

None.

References

1. Hebert SC: Bartter syndrome. *Curr Opin Nephrol Hypertens* 12: 527-532, 2003
2. Reinalter SC, Jack N, Peters M, Seyberth HW: Pharmacotyping of salt-losing tubular disorders. *Acta Physiol Scand* 181: 513-521, 2004
3. Colussi G: Bartter syndrome. Orphanet encyclopedia, March 2005. Available at: <http://www.orpha.net/data/patho/GB/uk-Bartter.pdf>
4. Rose BD: Causes of hypokalemia. In: *UpToDate*, ver. 14.1, edited by Rose BD, Waltham, MA, UpToDate, 2005
5. Colussi G, Rombola G, Airaghi C, De Ferrari ME, Minetti L: Pseudo-Bartter's syndrome from surreptitious diuretic intake: Differential diagnosis with true Bartter's syndrome. *Nephrol Dial Transplant* 7: 896-901, 1992
6. Glazwiza U, Schwarz R, Gitter AH, Bijman J, Seyberth H, Beck F, Gross P: Chronic hypokalemia of adults: Gitelman's syndrome is frequent, but classical Bartter's syndrome is rare. *Nephrol Dial Transplant* 10: 1607-1613, 1995
7. Lemmink HH, Knoers NV, Karolyi L, van Dijk H, Niaudet P, Antignac C, Guay-Woodford LM, Goodyer PR, Carel JC, Hermes A, Seyberth HW, Monnens LA, van den Heuvel LP: Novel mutations in the thiazide-sensitive NaCl cotransporter gene in patients with Gitelman syndrome with predominant localization to the C-terminal domain. *Kidney Int* 54: 720-730, 1998
8. Puschett JB, Greenberg A, Mitro R, Piraino B, Wallia R: Variant of Bartter's syndrome with a distal tubular rather than loop of Henle defect. *Nephron* 50: 205-211, 1988
9. Sutton RA, Mavichak V, Halabe A, Wilkins GE: Bartter's syndrome: Evidence suggesting a distal tubular defect in a

- hypocalciuric variant of the syndrome. *Miner Electrolyte Metab* 18: 43–51, 1992
10. Colussi G, Rombola G, Brunati C, De Ferrari ME: Abnormal reabsorption of Na/Cl by the thiazide-inhibitable transporter of the distal convoluted tubule in Gitelman's syndrome. *Am J Nephrol* 17: 103–111, 1997
 11. Kockerling A, Reinalter SC, Seyberth HW: Impaired response to furosemide in hyperprostaglandin E syndrome: Evidence for a tubular defect in the loop of Henle. *J Pediatr* 129: 519–528, 1996
 12. Bettinelli A, Vezzoli G, Colussi G, Bianchetti MG, Sereni F, Casari G: Genotype-phenotype correlations in normotensive patients with primary renal tubular hypokalemic metabolic alkalosis. *J Nephrol* 11: 61–69, 1998
 13. Mastroianni N, Bettinelli A, Bianchetti M, Colussi G, De Fusco M, Sereni F, Ballabio A, Casari G: Novel molecular variants of the Na-Cl cotransporter gene are responsible for Gitelman syndrome. *Am J Hum Genet* 59: 1019–1026, 1996
 14. Syren ML, Tedeschi S, Cesareo L, Bellantuono R, Colussi G, Procaccio M, Ali A, Domenica R, Malcerti F, Sprocati M, Sacco M, Biglietti N, Edefonti A, Sereni F, Casari G, Coviello DA, Bettinelli A: Identification of fifteen novel mutations in the SLC12A3 gene encoding the Na-Cl Co-transporter in Italian patients with Gitelman syndrome. *Hum Mutat* 20: 78–82, 2002
 15. Simon DB, Karet FE, Hamdan JM, Di Pietro A, Sanjad SA, Lifton RP: Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. *Nat Genet* 13: 183–188, 1996
 16. Konrad M, Vollmer M, Lemmink HH, Lambertus P, van den Heuvel LP, Jeck N, Vargas-Poussou R, Lakings A, Ruf R, Deschenes G, Antignac C, Guay-Woolford L, Knoers NV, Seyberth HW, Feldmann D, Hildebrandt F: Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. *J Am Soc Nephrol* 11: 1449–1459, 2000
 17. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP: Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. *Nat Genet* 17: 171–178, 1997
 18. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP: Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K⁺ channel, ROMK. *Nat Genet* 14: 152–156, 1996
 19. Colussi G, De Ferrari ME, Tedeschi S, Prandoni S, Syren ML, Civati G: Bartter's syndrome type 3: An unusual cause of nephrolithiasis. *Nephrol Dial Transplant* 17: 521–523, 2002
 20. Colussi G, Macaluso M, Brunati C, Minetti L: Calcium metabolism and calciotropic hormone levels in Gitelman's syndrome. *Miner Electrolyte Metab* 20: 294–301, 1994
 21. Bettinelli A, Bianchetti MG, Girardin E, Caringella A, Cecconi M, Claris Appiani A, Pavanello L, Gastaldi RC, Isimbaldi C, Lama G, Marchesoni C, Matteucci C, Patriarca P, Di Natale B, Setzu C, Vitucci P: Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. *J Pediatr* 120: 38–43, 1992
 22. Danovitch GM: Clearance methodology in the study of the function of the distal tubule. *Ren Physiol* 1: 56–60, 1978
 23. Rombola G, Colussi G, De Ferrari ME, Surian M, Malberti F, Minetti L: Clinical evaluation of segmental tubular reabsorption of sodium and fluid in man: Lithium vs free water clearances. *Nephrol Dial Transplant* 2: 212–218, 1987
 24. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP: Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. *Nat Genet* 12: 24–30, 1996
 25. Birkenhager R, Otto E, Schurmann MJ, Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekmann F, Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, Knoers NV, Antignac C, Sudbrak R, Kispert A, Hildebrandt F: Mutation of BSND causes Bartter syndrome with sensori-neural deafness and kidney failure. *Nat Genet* 29: 310–314, 1997
 26. Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Paillard M, Planelles G, Dechaux M, Miller RT, Antignac C: Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. *J Am Soc Nephrol* 13: 2259–2266, 2002
 27. Buratti E, Baralle FE, Pagani F: Can a 'patch' in a skipped exon make the pre-mRNA splicing machine run better? *Trends Mol Med* 9: 229–232, 2003
 28. Peters M, Jeck N, Reinalter S, Leonhardt A, Tonshoff B, Klaus GG, Konrad M, Seyberth HW: Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. *Am J Med* 112: 183–190, 2002
 29. Zelikovic I, Szargel R, Hawash A, Labay V, Hatib I, Cohen N, Nakhoul F: A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndrome. *Kidney Int* 63: 24–32, 2003
 30. Bettinelli A, Borsa N, Syren ML, Mattiello C, Coviello D, Edefonti A, Giani M, Travi M, Tedeschi S: Simultaneous mutations in the CLCNKB and SLC12A3 genes in two siblings with phenotypic heterogeneity in classic Bartter syndrome. *Pediatr Res* 58: 1269–1273, 2005
 31. Rose BD, Post TW: Mechanism of action of diuretics. In: *UpToDate*, ver. 14.1, edited by Rose BD, Waltham, MA, UpToDate, 2005
 32. De Jong JC, Van Der Vliet WA, Van Den Heuvel LP, Willems PH, Knoers NV, Bindels RJ: Functional expression of mutations in the human NaCl cotransporter: Evidence for impaired routing mechanisms in Gitelman's syndrome. *J Am Soc Nephrol* 13: 1442–1448, 2002
 33. Jang HR, Lee JW, Oh YK, Na KY, Joo KW, Jeon US, Cheong HI, Kim J, Han JS: From bench to bedside: Diagnosis of Gitelman's syndrome—Defect of sodium-chloride cotransporter in renal tissue. *Kidney Int* 70: 813–817, 2006
 34. Loon NR, Wilcox CS, Unwin RJ: Mechanism of impaired natriuretic response to furosemide during prolonged therapy. *Kidney Int* 36: 682–689, 1989
 35. Fliser D, Schroter M, Neubeck M, Ritz E: Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. *Kidney Int* 46: 482–488, 1994
 36. Fukuyama S, Hiramatsu M, Akagi M, Higa M, Ohta T: Novel mutation of the chloride channel K_b gene in two Japanese patients clinically diagnosed as Bartter syndrome with hypocalciuria. *J Clin Endocrinol Metab* 89: 5847–5850, 2004
 37. Kobayashi K, Uchida S, Mizutani S, Sasaki S, Marumo F: Intrarenal and cellular localization of CLC-K2 protein in the mouse kidney. *J Am Soc Nephrol* 12: 1327–1334, 2001